Highlights The first incretin hormone, gastric inhibitory peptide, was identified in the early 1970s, followed by the discovery of glucagonlike peptide 1 (GLP-1) in the 1980s [1]
Some possible peptide therapy side effects include: Hives, swelling, or breathing difficulty High blood pressure, rapid heart rate, and palpitations Nausea, vomiting, and diarrhea Headaches and dizziness Rashes Always consult a doctor before starting peptide therapy
Consult a qualified healthcare professional before making any health decision, and verify the legal status of these compounds in your jurisdiction
Brain potential evidence for an auditory sensory memory deficit in schizophrenia
In fact, results may vary depending on skin type and condition